Effect of Ketoconazole on the plasma pharmacokinetics of Axitinib (AG-013736) in healthy volunteers

被引：0
作者：
Pithavala, Yazdi
Klamerus, Karen
Garrett, May
Hee, Brian
Mount, Janessa
Selaru, Paulina
Sarapa, Nenad
机构：
[1] Pfizer Inc, San Diego, CA USA
[2] CPCS Pharma Consulting, Morristown, NJ USA
来源：
CANCER RESEARCH | 2008年 / 68卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
232
引用
收藏
页数：2
相关论文
共 50 条
[31]   A phase 2 study of axitinib (AG-013736), a potential inhibitor of VEGFRs, in patients with advanced thyroid cancer [J].
Cohen, R. ;
Vokes, E. E. ;
Rosen, L. ;
Kies, M. S. ;
Worden, F. P. ;
Kane, M. A. ;
Forastiere, A. A. ;
Liau, K. ;
Bycott, P. ;
Cohen, E. E. W. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (02) :S136-S136
[32]   PHASE I STUDY OF AXITINIB (AG-013736) IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS (PTS) WITH ADVANCED SOLID TUMOURS [J].
Martin, L. P. ;
Kozloff, M. ;
Herbst, R. S. ;
Samuel, T. A. ;
Kim, S. ;
Rosbrook, B. ;
Tortorici, M. ;
Tarazi, J. ;
Olszanski, A. J. ;
Cohen, R. B. .
ANNALS OF ONCOLOGY, 2008, 19 :157-157
[33]   Axitinib (AG-013736), an Oral Specific VEGFR TKI, Shows Potential Therapeutic Utility Against Cholangiocarcinoma [J].
Takahashi, Hiroyuki ;
Ojima, Hidenori ;
Shimizu, Hiroko ;
Furuse, Junji ;
Furukawa, Hiroyuki ;
Shibata, Tatsuhiro .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (06) :570-578
[34]   Axitinib (AG-013736) and gemcitabine vs gemcitabine in advanced pancreatic cancer: a randomised phase II study [J].
Spano, J. ;
Chodkiewicz, C. ;
Maurel, J. ;
Wong, R. ;
Wasan, H. S. ;
Barone, C. ;
Liau, K. F. ;
Pithavala, Y. ;
Bycott, P. W. ;
Rixe, O. .
EJC SUPPLEMENTS, 2007, 5 (04) :261-261
[35]   EFFECT OF KETOCONAZOLE AND TERBINAFINE ON THE PHARMACOKINETICS OF CAFFEINE IN HEALTHY-VOLUNTEERS [J].
WAHLLANDER, A ;
PAUMGARTNER, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (03) :279-283
[36]   A randomised phase 2 study of axitinib (AG-013736) and gemcitabine vs gemcitabine in advanced pancreatic cancer [J].
Spano, J. ;
Chodkievvicz, C. ;
Maurel, J. ;
Wong, R. ;
Singh, Wasan H. ;
Barone, C. ;
Liau, K. ;
Pithavala, Y. ;
Bycott, P. ;
Kim, S. ;
Rixe, O. .
ANNALS OF ONCOLOGY, 2007, 18 :VII14-VII14
[37]   Antiangiogenic inhibitor axitinib (AG-013736) renders significant growth inhibition of bevacizumab-refractory xenograft tumors [J].
Hu-Lowe, D. ;
Grazzini, M. ;
Amundson, K. ;
Wickman, G. ;
Qiu, M. ;
Kang, D. ;
Los, G. ;
Chen, E. .
EJC SUPPLEMENTS, 2006, 4 (12) :25-25
[38]   A phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. [J].
Kim, S. ;
Rosen, L. S. ;
Cohen, E. E. ;
Cohen, R. B. ;
Forastiere, A. ;
Silva, A. M. ;
Liau, K. F. ;
Archer, R. L. ;
Bycott, P. ;
Vokes, E. E. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :287S-287S
[39]   Health-related quality of life in patients with metastatic renal cell carcinoma treated with axitinib (AG-013736) [J].
Trask, P. C. ;
Bushmakin, A. G. ;
Cappelleri, J. C. ;
Kim, S. ;
Bycott, P. W. ;
Liau, K. F. .
VALUE IN HEALTH, 2007, 10 (03) :A140-A140
[40]   LEVOTHYROXIN TREATMENT OF HYPOTHYROIDISM AND AXITINIB (AG-013736) EFFICACY IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) [J].
Dutcher, J. P. ;
Rixe, O. ;
Motzer, R. J. ;
Wilding, G. ;
Stadler, W. M. ;
Kim, S. ;
Tarazi, J. ;
Rosbrook, B. ;
Rini, B. .
ANNALS OF ONCOLOGY, 2008, 19 :194-194
12345